Targeting hormone-resistant breast cancer cells with docetaxel: a look inside the resistance

Alexander M Scherbakov; Anna A Basharina; Danila V Sorokin; Ekaterina I Mikhaevich; Iman E Mizaeva; Alexandra L Mikhaylova; Tatiana A Bogush; Mikhail A Krasil'nikov

doi:10.20517/cdr.2022.96

Targeting hormone-resistant breast cancer cells with docetaxel: a look inside the resistance

Cancer Drug Resist. 2023 Feb 7;6(1):103-115. doi: 10.20517/cdr.2022.96. eCollection 2023.

Authors

Alexander M Scherbakov¹, Anna A Basharina², Danila V Sorokin¹, Ekaterina I Mikhaevich¹, Iman E Mizaeva², Alexandra L Mikhaylova¹, Tatiana A Bogush², Mikhail A Krasil'nikov¹

Affiliations

¹ Department of Experimental Tumor Biology, Blokhin N.N. National Medical Research Center of Oncology, Moscow 115522, Russian Federation.
² Group of Molecular Tumor Markers, Blokhin N.N. National Medical Research Center of Oncology, Moscow 115522, Russian Federation.

Abstract

Aim: The study aims to analyze the effect of long-term incubation of ERα-positive MCF7 breast cancer cells with 4-hydroxytamoxifen (HT) on their sensitivity to tubulin polymerization inhibitor docetaxel. Methods: The analysis of cell viability was performed by the MTT method. The expression of signaling proteins was analyzed by immunoblotting and flow cytometry. ERα activity was evaluated by gene reporter assay. To establish hormone-resistant subline MCF7, breast cancer cells were treated with 4-hydroxytamoxifen for 12 months. Results: The developed MCF7/HT subline has lost sensitivity to 4-hydroxytamoxifen, and the resistance index was 2. Increased Akt activity (2.2-fold) and decreased ERα expression (1.5-fold) were revealed in MCF7/HT cells. The activity of the estrogen receptor α was reduced (1.5-fold) in MCF7/HT. Evaluation of class III β-tubulin expression (TUBB3), a marker associated with metastasis, revealed the following trends: higher expression of TUBB3 was detected in triple-negative breast cancer MDA-MB-231 cells compared to hormone-responsive MCF7 cells (P < 0.05). The lowest expression of TUBB3 was found in hormone-resistant MCF7/HT cells (MCF7/HT < MCF7 < MDA-MB-231, approximately 1:2:4). High TUBB3 expression strongly correlated with docetaxel resistance: IC₅₀ value of docetaxel for MDA-MB-231 cells was greater than that for MCF7 cells, whereas resistant MCF7/HT cells were the most sensitive to the drug. The accumulation of cleaved PARP (a 1.6-fold increase) and Bcl-2 downregulation (1.8-fold) were more pronounced in docetaxel-treated resistant cells (P < 0.05). The expression of cyclin D1 decreased (2.8-fold) only in resistant cells after 4 nM docetaxel treatment, while this marker was unchanged in parental MCF7 breast cancer cells. Conclusion: Further development of taxane-based chemotherapy for hormone-resistant cancer looks highly promising, especially for cancers with low TUBB3 expression.

Keywords: 4-hydroxytamoxifen; Cancer; breast cancer; class III β-tubulin; docetaxel; estrogen receptors alpha; resistance.